Table 2.
Summary of iPSC cell lines used in this study
| Cell line | Condition | Sex | Age | Reprogramming method | Source/References |
|---|---|---|---|---|---|
| 18a (Ctrl #1) | Non-neurological control | Female | 51 | Retrovirus | Boulting et al. [63]; Nat Biotechnol |
| 11a (Ctrl #2) | Non-neurological control | Male | 36 | Retrovirus | Boulting et al. [63]; Nat Biotechnol |
| 15-12 (Ctrl #3) | Non-neurological control | Male | 36 | Sendai | RUCDR Infinite Biologics |
| CS0002 (Ctrl#4) | Non-neurological control | Male | 51 | Episomal | Cedars Sinai/Answer ALS |
| C9#3.1 (C9-ALS #1) | C9-ALS | Female | 64 | Sendai | RUCDR Infinite Biologics |
| C910689 (C9-ALS #2) | C9-ALS | Female | 51 | Sendai and episomal | Coriell Institute for Medical Research |
| C9#2 (C9-ALS #3) | C9-ALS | Female | 61 | Sendai | RUCDR Infinite Biologics |